Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May 3:10:639.
doi: 10.3332/ecancer.2016.639. eCollection 2016.

Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival

Nicoletta Biglia  1 , Paola Sgandurra  2 , Valentina Elisabetta Bounous  1 , Furio Maggiorotto  2 , Eleonora Piva  3 , Emanuele Pivetta  4 , Riccardo Ponzone  2 , Barbara Pasini  5
Affiliations

Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival

Nicoletta Biglia et al. Ecancermedicalscience. .

Abstract

Objectives: To compare clinical-pathological characteristics and outcome between sporadic ovarian cancer and ovarian cancer in patents with hereditary breast and ovarian cancer syndrome (HBOC).

Methods: Twenty-four patients with ovarian cancer treated between 2000 and 2009 who tested positive for BRCA1/2 mutation (BRCA+) and a control group of 64 age-matched patients with no family history of breast/ovarian cancer (controls) were enrolled. Clinical-pathological characteristics, surgical outcome, overall (OS), and progression-free survival (PFS) were compared between the two groups.

Results: The high-grade serous histotype was more represented in BRCA+ than in controls (70.8% versus 53.1%) (p > 0.05). BRCA+ cancers were more frequently diagnosed at stage II than controls (20.83% versus 4.69%) (p = 0.024). Radical primary surgery was performed in 70% of women in both groups, with no difference in debulking results. In patients undergoing surgery after neoadjuvant chemotherapy, in all BRCA+ patients, optimal cytoreduction was achieved (versus 70% of the controls). PFS was significantly longer for BRCA+ patients compared to controls (60 months versus 22 months; p = 0.039). No significant difference was observed in OS between BRCA+ patients and controls.

Conclusions: At a median follow-up time of 46 months, BRCA+ patients have a better prognosis than controls in terms of PFS. Higher chemosensitivity of BRCA+ tumours was observed.

Keywords: BRCA1; BRCA2; gene mutations; hereditary breast and ovarian cancer syndrome; ovarian cancer; prognosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Progression-free survival (PFS) in the BRCA+ group compared to controls.
See this image and copyright information in PMC

References

    1. Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol. 2003;88:S8–10. doi: 10.1006/gyno.2002.6674. - DOI - PubMed
    1. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260–5. doi: 10.1001/jama.283.17.2260. - DOI - PubMed
    1. Synowiec A, Wcisło G, Bodnar L, et al. Hereditary Cancer in Clinical Practice. 2016;14:1. - PMC - PubMed
    1. Werness BA, Ramus SJ, Whittemore AS, et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCAI mutations. Hum Pathol. 2000;31:1420–4. doi: 10.1016/S0046-8177(00)80014-3. - DOI - PubMed
    1. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2127–9. doi: 10.1002/cncr.11310. - DOI - PubMed